{"id":389007,"date":"2024-12-20T00:00:00","date_gmt":"2024-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2024-biopharma-type-2-diabetes-disease-landscape-forecast-g7-2024\/"},"modified":"2026-04-29T23:11:52","modified_gmt":"2026-04-29T23:11:52","slug":"dlsfmd0004-2024-biopharma-type-2-diabetes-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2024-biopharma-type-2-diabetes-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Type 2 Diabetes | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity of several key T2D brands such as the dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists will exert downward pressure on market sales. Nonetheless, the launch and uptake of Eli Lilly\u2019s first-in-class, glucose-dependent insulinotropic polypeptide (GIP) \/ GLP-1 receptor agonist, Mounjaro, and other late-phase therapies will support the T2D market through 2033. Significant unmet need remains for disease-modifying therapies that can offer a better quality of life and reduce the treatment burden of intensive combination therapy.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the drivers and constraints in the T2D market, and how will the market evolve over the forecast period?<\/li>\n<li>How has the launch of Eli Lilly\u2019s tirzepatide (Mounjaro) affected the prescribing of GLP-1 receptor agonists such as Eli Lilly\u2019s Trulicity and Novo Nordisk\u2019s Ozempic in the United States and Japan? How will the therapy be received in the European markets?<\/li>\n<li>How will the launch of nonbranded therapies affect the G7 T2D market?<\/li>\n<li>What do key opinion leaders think about emerging therapies such as Novo Nordisk\u2019s insulin icodec and CagriSema?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<ul>\n<li><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/li>\n<li><strong>Primary research: <\/strong>19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology: <\/strong>Prevalence of T2D by country with population-specific diagnosed and drug-treated rates.<\/li>\n<li><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key T2D therapies through 2033, segmented by brands \/ generics.<\/li>\n<li><strong>Emerging therapies:<\/strong> Phase 3\/PR: 5 drugs<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>KEY FEATURES<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389007","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389007\/revisions"}],"predecessor-version":[{"id":575855,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389007\/revisions\/575855"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}